Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.32 0.28 (1.27%) Market Cap: 1.61 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 58/100

Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 06:30PM GMT
Release Date Price: $11.11 (+1.37%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the afternoon session of the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, [Malcom Kuno] and [Jadel] Smith from the team.

Our next presenting company is Kiniksa and presenting on behalf of the company, we have CEO, Sanj Patel. (Operator Instructions) With that, Sanj, take it away.

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Thanks, Anupam. It's good to be here again, albeit virtually, and thanks also to JPMorgan for hosting us today. I'm happy to highlight the commercial launch of our first approved product, ARCALYST, which is up to a very strong start. I'll also review our pipeline, which includes additional immune modulating assets, all of which have the potential for multiple follow-on indications.

There's a lot to cover, so let's get started. First, please note that I will be making forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot